Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fenofibrate potentiates warfarin effects.

Karissa Y Kim1, Michael A Mancano

  • 1Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA 19140-5101, USA. karissa.kim@temple.edu

The Annals of Pharmacotherapy
|January 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atorvastatin-Induced Fixed Drug Eruption Clopidogrel-Induced Acute Hepatitis Bilateral Angle-Closure Glaucoma Induced by Chlorthalidone Risk of Anaphylactic Reactions with Intravenous Iron Products Zonisamide-Induced DRESS with Eosinophilic Pneumonia.

Hospital pharmacy·2024
Same author

Vemurafenib-Induced Dupuytren's Contracture; Levetiracetam-Induced Rage and Increased Risk of Suicide; PPD Tuberculin Skin Test-Induced Deep Necrotic Skin Lesion; Voriconazole-Induced Phototoxicity, Pseudoporphyria, and Photo-Onycholysis; Dronedarone-Induced Organizing Pneumonia.

Hospital pharmacy·2024
Same author

Fenofibrate-Induced Immune Thrombocytopenia; Topical Pramoxine-Induced Anaphylaxis; Nexplanon Delayed Hypersensitivity; Cyclosporine-Induced Cutaneous Pseudolymphoma; Severe Acute Hepatitis with Intravenous Amiodarone; Herpes-like Skin Eruption Due to Fluconazole.

Hospital pharmacy·2024
Same author

ISMP Adverse Drug Reactions: Pheochromocytoma Crisis Induced by Metoclopramide Baclofen Dependence Following High-Dose Therapy Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Acute Anterograde Amnestic Syndrome Induced by Fentanyl Ivermectin-Induced Toxic Epidermal Necrolysis Pembrolizumab-Induced Type 1 Diabetes.

Hospital pharmacy·2019
Same author

ISMP Adverse Drug Reactions: Longitudinal Thumbnail Fissures Due to Erlotinib Priapism Associated With the Use of ExtenZe Blindness From a Nevirapine-Based HAART Regimen Hyperprolactinemia and Galactorrhea Due to Aripiprazole Trypophobia Associated With Gabapentin Coadministered Linezolid and Methadone Cause Serotonin Syndrome.

Hospital pharmacy·2019
Same author

ISMP Adverse Drug Reactions: Lithium-Induced Cardiomyopathy Fixed Drug Eruption Due to Cetirizine, Levocetirizine, and Hydroxyzine Nivolumab-Induced Myasthenia Gravis Nivolumab-Induced Cholangitic Liver Disease Torsade de Pointes Caused by Psychiatric Polypharmacy Trichotillomania Associated With Aripiprazole.

Hospital pharmacy·2018

Fenofibrate significantly increases warfarin's anticoagulant effect, necessitating dosage adjustments. Monitoring international normalized ratio (INR) is crucial when initiating fenofibrate alongside warfarin therapy.

Area of Science:

  • Pharmacology and Therapeutics
  • Drug Interactions
  • Cardiovascular Medicine

Background:

  • Warfarin is a widely used anticoagulant requiring careful management to maintain therapeutic efficacy and minimize bleeding risk.
  • Fenofibrate is a lipid-lowering agent commonly prescribed for dyslipidemia.

Observation:

  • Two patients on stable warfarin therapy experienced marked increases in their international normalized ratio (INR) after fenofibrate initiation.
  • These INR elevations necessitated significant reductions (30-40%) in warfarin dosage to maintain therapeutic anticoagulation.
  • Other potential contributing factors to the altered coagulation were systematically ruled out.

Findings:

  • Fenofibrate potentiated warfarin's anticoagulant effects, likely through a dual mechanism.

Related Experiment Videos

  • Potential mechanisms include displacement of warfarin from protein binding sites and inhibition of CYP2C9, the enzyme responsible for warfarin metabolism.
  • The observed drug interaction was classified as probable using the Naranjo probability scale.

    • Implications:

    • Clinicians should anticipate a potential interaction when prescribing fenofibrate to patients on warfarin.
    • Serial INR monitoring is recommended upon initiation of fenofibrate in patients receiving warfarin.
    • An initial empiric reduction in warfarin dosage (e.g., 20%) may be warranted, with further adjustments based on INR results.